Clinical trials: Glaucoma Eye
Glaucoma, Ocular Hypertension
Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry
While elevated intraocular pressure (IOP) is no longer part of the definition of glaucoma it remains the sole proven modifiable risk factor for the onset and progression of glaucoma.
- Trial name
- NCT04024293
- Testing
- Goldfish (GF)
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- Sensimed AG
Glaucoma, Open-Angle, Ocular Hypertension
Performance of the Travoprost Intraocular Implant
To evaluate the performance of the Travoprost Intracameral Implant by determining residual drug in explanted implants of the Travoprost Intracameral Implant and by determining aqueous humor concentrations of travoprost free acid…
- Trial name
- NCT06582732
- Testing
- Travoprost Intracameral Implant exchanged at Month 12, Travoprost Intracameral Implant exchanged at Month 3, Travoprost Intracameral Implant exchanged at Month 6
- Where
- Armenia
- Volunteers
- 210 people
- Sponsor
- Glaukos Corporation
Glaucoma, Ocular Hypertension
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of…
- Trial name
- NCT00440011
- Testing
- bimatoprost 0.03% eye drops, travoprost 0.004% eye drops
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Allergan
Glaucoma and Ocular Hypertension
Artificial Intelligence for Staging Glaucoma Severity: A Comparison With an Eye Specialist Using Visual Field Tests
The study titled "Reliability of Artificial Intelligence in Glaucoma Severity Staging Using the Brusini GSS2 System: A Longitudinal Comparative Study against Expert Assessment" aims to evaluate the diagnostic reliability and…
- Trial name
- AI-GSS2 (NCT07820709)
- Testing
- Artificial Intelligence GSS2 Staging
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Salerno
Refractory Primary Open Angle Glaucoma
Re-Trabeculectomy Versus Ahmed Glaucoma Valve Implantation in Secondary Surgical Management of Patients With Refractory Glaucoma
The purpose of this study is to compare three-year outcomes of re-trabeculectomy with those of Ahmed glaucoma valve implantation in secondary surgical management of patients with primary open angle glaucoma (POAG) and a history…
- Trial name
- NCT01633775
- Testing
- Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC
- Where
- 3 sites in Iran
- Volunteers
- 100 people
- Sponsor
- Vanak Eye Surgery Center
Glaucoma
Triamcinolone for Ahmed Glaucoma Valve
This triple-blind, stratified, randomized clinical trial includes 100 eyes of 100 patients aged 18 to 85 years with refractory glaucoma.
- Trial name
- NCT02653963
- Testing
- Adjunctival Triamcinolone
- Where
- Iran
- Volunteers
- 106 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Primary Open Angle Glaucoma or Ocular Hypertension
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.
- Trial name
- NCT03310580
- Testing
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 40 sites in United States
- Volunteers
- 42 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Benchmarking Management of Glaucoma Using the Diopsys VEP/PERG Protocols.
Establish electrophysiological benchmarks, using the Diopsys Visual Evoked Potential/ Pattern ERG (VEP/PERG) protocols of populations with Glaucoma following: 1) Baseline VEP/ERG prior to treatment; and 2) VEP/PERG after…
- Trial name
- NCT02594280
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Diopsys, Inc.
Glaucoma, Ocular Hypertension
A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
Double blind, crossover randomized, multicentric study to compare efficacy and tolerability of concomitant administration of travoprost and brinzolamide versus timolol-dorzolamide fixed combination in patients with glaucoma or…
- Trial name
- NCT00471380
- Testing
- travoprost 0.004% and brinzolamide 1%, fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle
- Where
- Italy
- Volunteers
- 46 people
- Sponsor
- Alcon Research
Single-nucleotide Polymorphism (SNP) for Glaucoma
Investigation of Genetic Disease Marker Associated With Korean Glaucoma Patients
A single-nucleotide polymorphism (SNP) analysis of DNA obtained from peripheral blood of the glaucoma patients and the normal control will be performed to find genetic marker for primary open angle glaucoma.
- Trial name
- NCT01025024
- Testing
- SNP analysis of the DNA
- Where
- South Korea
- Volunteers
- 1,224 people, healthy volunteers welcome
- Sponsor
- Chungnam National University
Sturge-Weber Syndrome (SWS), Glaucoma
A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101
Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
- Conditions
- Sturge-Weber Syndrome (SWS), Glaucoma, Glaucoma Congenital, Ocular Hypertension
- Trial name
- NCT04947124
- Testing
- QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2%
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Qlaris Bio, Inc.
Ocular Hypertension
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Bimatoprost/Timolol Fixed Combination in patients with glaucoma or ocular hypertension
- Trial name
- NCT00332059
- Testing
- bimatoprost/timolol fixed combination
- Where
- 4 sites in United States, Austria and 2 more
- Volunteers
- 445 people
- Sponsor
- Allergan
Refractive Error, Glaucoma
A Post-market Clinical Study to Collect Safety and Performance Data on Johnson & Johnson Surgical Vision Products
Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.
- Conditions
- Refractive Error, Glaucoma, Cataracts, Clear Lens Exchange
- Trial name
- NCT05394324
- Testing
- Intervention
- Where
- 13 sites in United States, Germany and 1 more
- Volunteers
- 1,674 people
- Sponsor
- Johnson & Johnson Surgical Vision, Inc.
Glaucoma, Retinal Disease
OCT Agreement and Crossed Precision Study
The purpose of this study is to asses the agreement of the RS-3000 Lite and RS-3000 Advance to the RS-3000, assess the crossed precision of each study device and to assess the transference of a reference database from the RS-3000…
- Conditions
- Glaucoma, Retinal Disease, Corneal Disease
- Trial name
- NCT02050880
- Where
- United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Nidek Co. LTD.
Glaucoma
The AVB Study: Prospective Study Comparing the Ahmed Valve and the Baerveldt Implant for Treating Refractory Glaucoma
The purpose of this study is to compare the safety and efficacy of the Ahmed valve and the Baerveldt implant in treating refractory glaucoma.
- Trial name
- NCT00940823
- Testing
- Ahmed FP7 Valve, Baerveldt-350 Tube
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 238 people
- Sponsor
- Credit Valley EyeCare
Postoperative Cognitive Disorder, Glaucoma
Application of Innovative Non-Invasive Neuroprotective Technology in Cardiac Surgery and Ophthalmology
Postoperative cognitive dysfunction (POCD) and delirium (incidence up to 42 %) after cardiac surgery with cardiopulmonary bypass (CPB) are common postoperative complications that impair the patient's quality of life and increase…
- Trial name
- NCT04943458
- Testing
- Monitoring of cerebral autoregulation
- Where
- Lithuania
- Volunteers
- 270 people
- Sponsor
- Milda Svagzdiene
Glaucoma
Glaucoma Rehabilitation Using ElectricAI Transcranial Stimulation (GREAT) - Randomized Controlled Trial Using Combined Perceptual Learning and Transcranial Electrical Stimulation for Vision Enhancement
Glaucoma is a complex disease that can result in progressive vision loss. It is the second leading cause of blindness, accounting for 23% of permanent blindness in Hong Kong.
- Trial name
- NCT05874258
- Testing
- Real-PL training + Real-tES(tDCS)
- Where
- Hong Kong
- Volunteers
- 144 people
- Sponsor
- The Hong Kong Polytechnic University
Glaucoma
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.
- Trial name
- NCT00347841
- Testing
- Bimatoprost 0.03%, Latanoprost
- Where
- United States
- Sponsor
- Innovative Medical
Glaucoma, Fractional Anisotropy
Analysis of Visual Pathways in Glaucoma Patients Using a 3tesla-MRI
Glaucoma is a neurodegenerative disease representing the second cause of blindness worldwide. IOP (Intra occular pressure) is the most common risk factor, but not the only one as it is observed for normal tension glaucoma.
- Trial name
- ENVOL (NCT01621841)
- Testing
- examination MRI 3T (Magnetic Resonance Imaging 3 Telsa), increasing spatial resolution and DTI (diffusion tensor Imaging) with fractional anisotropy
- Where
- France
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Glaucoma, Primary Open Angle, Ocular Hypertension
A Study of LUMIGAN® RC in the Clinical Setting
This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.
- Trial name
- NCT01833741
- Testing
- Bimatoprost 0.01%
- Where
- Canada
- Volunteers
- 1,137 people
- Sponsor
- Allergan